Table 1 |
|||
|
Comparative anti-HIV-1 efficacy of MnTBAP in macrophages and lymphocytes |
|||
|
Cells |
EC50 (mM) |
EC90 (mM) |
TC50 (mM) |
|
|
|||
|
Macrophages |
|||
|
Acutely infected |
3.7 (± 0.05) |
19.5 (± 0.5) |
60 |
|
Cronically infected |
6.3 (± 0.003) |
30 (± 0.6) |
60 |
|
Limphocytes |
|||
|
Acutely infected |
7.4 (± 0.06) |
21.3 (± 0.6) |
50 |
|
|
|||
|
The geometric mean of p24 gag Ag production of replicates in each experiment was used to determine the effective drug concentration where 50% and 90% of viral replication is inhibited (EC50 and EC90, respectively), by linear regression of the log of the percent HIV-1-p24 production (compared to untreated controls) versus the log of the drug concentration. TC50: toxic concentration 50%; drug toxicity has been assessed in the absence of viral infection. |
|||
|
Aquaro et al. Retrovirology 2007 4:76 doi:10.1186/1742-4690-4-76 |
|||
